Research programme: enterovirus A vaccine - Sentinext Therapeutics

Drug Profile

Research programme: enterovirus A vaccine - Sentinext Therapeutics

Alternative Names: STX 100/Alhydrogel

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sentinext Therapeutics
  • Class Enterovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Enterovirus A infections

Most Recent Events

  • 18 Jul 2017 Enterovirus A vaccine is still in early research for Enterovirus A infection in Malaysia (Parenteral)(ACTRN12617001027303)
  • 17 Jul 2017 Sentinext Therapeutics plans a phase I trial of STX 100/Alhydrogel (In volunteers, Parenteral) in July 2017 (ACTRN12617001027303)
  • 16 Jul 2016 No recent reports of development identified for research development in Enterovirus A infections in Malaysia (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top